Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

SML2591

Sigma-Aldrich

SCH-39166 hydrobromide

≥98% (HPLC)

Sinonimo/i:

(-)-trans-6,7,7a,8,9,13b-Hexahydro-3-chloro-2-hydroxy-N-methyl- 5H-benzo[d]naptho-(2,1-b)azepine hydrobromide, (6aS,13bR)-11-Chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-12-ol hydrobromide, (6aS-trans)-11-Chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-Benzo[d]naphth[2,1-b]azepin-12-ol hydrobromide, Ecopipam hydrobromide, PSYRX 101 hydrobromide, PSYRX-101 hydrobromide, PSYRX101 hydrobromide, SCH 39166 hydrobromide, SCH39166 hydrobromide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C19H20ClNO·HBr
Numero CAS:
Peso molecolare:
394.73
Numero MDL:
Codice UNSPSC:
12352200
NACRES:
NA.77

Saggio

≥98% (HPLC)

Forma fisica

powder

Condizioni di stoccaggio

desiccated

Colore

white to beige

Solubilità

DMSO: 2 mg/mL, clear

Temperatura di conservazione

2-8°C

Azioni biochim/fisiol

SCH-39166 (ecopipam) is a high-affinity D1/D5 subtype-selective dopamine receptor antagonist (Ki = 1.2 nM/D1, 2.0 nM/D5, 980 nM/D2, 5.52 μM/D4, 80 nM/5-HT, 731 nM/α2a). SCH-39166 is widely employed both in cultures and in animal studies in vivo.

Pittogrammi

Exclamation mark

Avvertenze

Warning

Indicazioni di pericolo

Classi di pericolo

STOT SE 3

Organi bersaglio

Central nervous system

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Brendan D Hare et al.
Nature communications, 10(1), 223-223 (2019-01-16)
Impaired function in the medial prefrontal cortex (mPFC) contributes to depression, and the therapeutic response produced by novel rapid-acting antidepressants such as ketamine are mediated by mPFC activity. The mPFC contains multiple types of pyramidal cells, but it is unclear
Meera E Modi et al.
Frontiers in molecular neuroscience, 11, 107-107 (2018-07-05)
Mutations in the SHANK family of genes have been consistently identified in genetic and genomic screens of autism spectrum disorder (ASD). The functional overlap of SHANK with several other ASD-associated genes suggests synaptic dysfunction as a convergent mechanism of pathophysiology
Yang Yang et al.
Molecular psychiatry (2018-12-12)
Dopamine D1 agonists enhance cognition, but the role of different signaling pathways (e.g., cAMP or β-arrestin) is unclear. The current study compared 2-methyldihydrexidine and CY208,243, drugs with different degrees of both D1 intrinsic activity and functional selectivity. 2-Methyldihydrexidine is a
Takeshi Enomoto et al.
Behavioral neuroscience, 132(6), 526-535 (2018-10-10)
Effort-based decision-making paradigms have recently been used to measure motivation in healthy subjects and patients with neuropsychiatric disorders. In the present study, we developed a novel effort-discounting paradigm using a touch-panel system in common marmosets. Marmosets were trained to choose
M A Tice et al.
Pharmacology, biochemistry, and behavior, 49(3), 567-571 (1994-11-01)
Characterization studies were conducted on the five cloned dopamine receptor subtypes (D1-D5) using the novel D1-selective antagonist, SCH 39166, as well as other related benzazepines and dopaminergic agents. The results demonstrate that SCH 39166 exhibits saturable, high-affinity binding to the

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.